Opinion|Videos|November 17, 2026

ROSELLA Trial Design, Survival Results, and Subgroup Findings

Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, and Ritu Salani, MD, MBA, of the David Geffen School of Medicine at UCLA, take a closer look at the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, and Ritu Salani, MD, MBA, of the David Geffen School of Medicine at UCLA, take a closer look at the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. Grisham summarizes the results: median overall survival of 16 versus 11.9 months, and a roughly 1-month gain in progression-free survival. Salani describes the design, with nab-paclitaxel given weekly for 3 weeks on and 1 week off in 28-day cycles and relacorilant taken the day before, day of, and day after each infusion, with G-CSF at the treating physician's discretion. She emphasizes hazard ratios of 0.65 for overall survival and 0.70 for progression-free survival, with curves that stay separated. Grisham notes the control arm used nab-paclitaxel at 100 mg/m² versus 80 mg/m² in the combination, and that phase 2 pharmacokinetic data showed equivalent taxane exposure. Prespecified subgroups, including prior PARP inhibitor and taxane use, all showed benefit.


Related to this article